Parkinson’s Disease - Drug Pipeline Analysis and Market Forecasts to 2015

The Parkinson’s Disease Therapeutics Market is Forecast to Show Slow Growth to 2015

Online PR News – 22-December-2009 – – GlobalData has estimated the global Parkinson’s disease (PD) market to be worth (US Dollars) $5.9 billion in 2008. It is forecast to grow at 0.9% annually for the next seven years to reach $6.4 billion by 2015. This low growth is primarily attributed to a weak pipeline landscape. The fact that the threat from generics, a weak pipeline and the unknown cause of the disease continue to pose significant challenges for prospective market entrants, the market landscape in the future is expected to remain static. With the increase in the ageing population, PD increasingly poses a huge healthcare challenge. This demographic shift will be a key driver in this market.

For further details, please or add the below link to your browser:

Most of the PD portfolio is maintained by small market players. Among the companies participating in the PD market, Merck Serono, Acadia, Axxonis, Avicena and Solvay were found to be the key players. Merck Serono and Avicena have one molecule each in Phase III for PD. Axxonis has the patch and subcutaneous form of one drug in Phase III, Acadia has one molecule in Phase III and one in the preclinical stage while Solvay has two drugs in Phase III development. Safinamide, Pimavanserin, PD-02 and SLV 308, currently in Phase III, are the key products in the pipeline. Safinamide, with features such as manifold mechanism of action and a high therapeutic index, remains the most keenly watched product in the pipeline. However, the fact that these pipeline products do not differ significantly from the marketed ones in terms of addressing the unmet clinical need or in offering superior medical benefits, the technological innovation landscape will remain unchanged in this market.

For further details, please or add the below link to your browser:

GlobalData analyzed that the current market landscape is weak due to limited options. The current market is primarily driven by combinations, reformulations, and indication expansions. Boehringer Ingelheim’s Mirapex/Sifrol is the market leader in the PD market. This is followed by Glaxo’s Requip/Requip XL and Orion/Novartis‘ Stalevo. Boehringer Ingelheim, GlaxoSmithKline (GSK), Orion/Novartis, Teva/Lundbeck remain the leading competitors in the global PD market. The competitive landscape is populated by four major products, none of which is significantly stronger or more dominant than the others. The currently marketed drug Azilect, has indicated to slow disease progression. On the positive side, key Phase III ADAGIO (Attenuation of Disease Progression with Azilect GIven Once-Daily) trial results will give boost to the PD market.
The high unmet needs imply that the market is not well served with current product options and therefore there is significant potential available to new entrants that would capture value from underserved segments. Designing disease-modifying drugs rather than those for providing symptomatic relief is one of the key challenges for this market and could provide a significant opportunity for any company.

GlobalData, the industry analysis specialist’s new report, “Parkinson’s Disease – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis, and identifies the key trends shaping and driving the global Parkinson’s disease (PD) market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Parkinson’s disease sector.

For further details, please or add the below link to your browser:

Or visit our report store: